outcome (P ¼ 0.0385). When stratified by ethnicity, the Caucasian cohort developed a significant difference in age of onset (84.025 vs 63.346 months, and P ¼ 0.0455, respectively) and the black cohort emerged with the most significant difference in age of onset (96.4 vs 58.444 months, and P ¼ 0.0226). The Hispanic cohort failed to develop a significant relationship between MDM2 polymorphism status and age of disease onset in either comparison (Figure 1 ).
Prognostic impact of vascular density and fibrosis in the bone marrow of children with high-risk acute lymphoblastic leukemia Leukemia (2005) It is now established that angiogenesis is important in solid tumors as well as in hematological diseases. 1 Whether measurements of angiogenesis can give prognostic information in childhood leukemia is however controversial. 2 To our knowledge micro vessel density (MVD) never has been shown to be of prognostic significance in any of the acute leukemias, childhood or adult. Fibrosis may complicate bone marrow (BM) disease and exerts in its advanced stage a negative influence on survival of patients due to BM failure, particularly in myeloproliferative disorders. 3 Several recent reports have shown that BM fibrosis evaluated by diverse methods is associated with a poor prognosis in CML. 4 The prognostic impact of BM fibrosis in childhood ALL has not been studied since the risk-stratified approach for treatment was introduced. The aim of the present study was to investigate the prognostic impact of MVD and reticulin fiber density (RFD) in the BM of children with newly diagnosed ALL.
BM iliac crest trephine biopsies obtained at diagnosis from all children 41 and o18 years of age (n ¼ 119) diagnosed with ALL between 1986 and 2001 at Umeå University Hospital were retrospectively studied. It was possible to evaluate both RFD and MVD in 81 BM biopsies. Samples were excluded when they were too crushed and distorted to be able to evaluate or when the total area possible to evaluate was less than three marrow spaces.
Diagnosis was established by morphology, immunophenotyping and cytogenetic analysis. The patients were treated according to the Swedish national ALL protocol from 1986 (n ¼ 25), and then according to the consecutive Nordic society of Pediatric Hematology and Oncology (NOPHO) ALL protocols from 1992 (n ¼ 52) and 2000 (n ¼ 4).
The patients stratified into standard risk or intermediate risk therapy in the 1986, 1992 and 2000 protocols were grouped together and classified as low-risk (LR) (n ¼ 54). The patients stratified into high-or very high-risk therapy in the 1986 and 1992 protocols were classified as high-risk (HR) in this study (n ¼ 27). No patients stratified to the high-risk treatment schedules in the 2000 protocol were included in this study. The mean follow-up was 7 years and 10 months for all patients, 8 years for the LR group and 7 years and 5 months for the HR group. Among the 22 relapsed patients in this material, 12 were LR and 10 were HR group patients. In all, 13 were early relapses (o6 months after end of therapy, seven LR and six HR) and nine were late relapses (46 months after end of therapy, five LR and four HR). This study was approved by the local ethical committee.
The BM biopsies were fixed in formaldehyde, decalcified and embedded in paraffin. Vessels were immunohistochemically identified with an antibody to von Willebrand Factor (anti-vWF). Micro vessel hot spot density (MVD) was measured as earlier described. 5, 6 Briefly, each of the biopsy samples was first scanned at Â 100 magnification, and at least three independent areas with abundant micro vessels were chosen and defined as hot spots. At Â 400 magnification in each hot spot a square lattice representing 0.06 mm 2 was adjusted until the maximum number of micro vessels for that hot spot was within the square. The micro vessels within that square were then counted. The MVD of a BM specimen was calculated as the mean value of the three hot spots with the highest MVD. Sections from the biopsies were also stained with silver impregnation for visualization of reticulin fiber content. 7 Reticulin fiber volume density (RFD): volume reticulin fibers/volume reference tissue, that is, the percentage of BM tissue occupied by reticulin fibers, was assessed in all samples. Using a 121-point eyepiece graticule at Â 400 magnification in 10 randomly selected fields within the marrow area, the number of graticule-crossing points (hits) overlaying reticulin fibers and hits over reference space (remaining BM area) were counted. 8 All estimations were done in a blinded manner by one investigator (UN-N). The MVD and RFD methods were both reproduced in a significant way (Po0.001).
The Mann-Whitney test was used to compare MVD and RFD for the nonrelapsed group and the relapsed group of patients. An event was defined as relapse of the disease. The time to an adverse event was defined as the interval in years between diagnosis and event. Patients were included until December 31, 2001, and the study ended June 30, 2004, thus children in continuous complete remission (CCR) were regarded as censored. The level of statistical significance was defined as P ¼ 0.05 (two-sided). All data was analyzed using SPSS 11.0.1 software for Windows (SPSS, Chicago, IL, USA).
The MVD had a normal distribution in the material and no difference was found between the LR and HR groups, respectively, regarding the distribution or mean of MVD. The RFD had a slightly skewed distribution with predominance of patients scoring 0. The result of the MVD and RFD measurements is shown in Table 1 . When comparing the LR and HR groups of patients the distribution was similar in both groups but the mean RFD for the LR group was significantly higher compared to the mean RFD for the HR patients (data not shown, P ¼ 0.016). When evaluating new prognostic factors it is important to analyze possible correlations to the traditional risk factors. In this study, MVD and WBC count were correlated in the HR group (Spearman rank correlation coefficient, r ¼ 0.58, Po0.001). This is illustrated in Figure 1 by a significantly higher mean of the WBC count in the group of patients with high MVD compared with the group of patients with low MVD. No correlation between RFD and other high-or low-risk features was found. However, this could be the result of lack of power and should be analyzed further. No significant correlation between MVD and RFD was found. To analyze if there was a difference in MVD or RFD between the relapsed and nonrelapsed patients, we compared the MVD and RFD values for these two groups. We found no association between MVD and relapse or for RFD and relapse for the whole group of patients (n ¼ 81) or for the LR patients (n ¼ 54). When analyzing the HR group (n ¼ 27), the MVD and the RFD were significantly higher in the relapsed group of patients compared to the nonrelapsed (P ¼ 0.018 and P ¼ 0.031, respectively, Figure 2 ). We did not find any significant difference in RFD or MVD between the early and late relapses (for definition see above).
To investigate the prognostic impact of MVD and RFD, we created Kaplan-Meier survival curves and performed Cox analysis. Cutoffs for MVD in the survival curves were decided by exploring data from MVD counts in Cox analysis dividing the material (n ¼ 81) in quartiles and thirds. The highest risk ratio (RR) was found for a group of patients recognized with a MVD Table 1 Mean and median values, range and cutoffs for micro vessel density (MVD), and reticulin fibre density (RFD) The WBC count in the HR group for the group of patients with MVD o13.5 compared to the group with MVD 413.5. P ¼ 0.001. J Represents outliers. cutoff value of 13.5, identical with the fourth quartile. The RFD data was explored in the same way and a RFD cutoff value of 14.2%, representing the upper third of patients, was found to give the most significant RR. The survival curves achieved using the mentioned cutoff for MVD showed a barely significant difference in pDFS between the groups of patients with low MVD -7676% -and the group with high MVD -54711% (P ¼ 0.05) -for all patients. When subdividing the material the survival curve for the LR group revealed no significant difference between the patients with low and high MVD. However, for the HR group the pDFS was significantly higher for the group of patients with low MVD (73710%, n ¼ 20) compared to the group of patients with high MVD (29717%, n ¼ 7, P ¼ 0.038).
The pDFS for the group of patients with low RFD -7776% -was compared with a pDFS of 57710% for the group with high RFD (P ¼ 0.047) in the survival curve achieved for all patients using the cutoff mentioned above. When subdividing the patients in the LR and HR groups the pDFS for the patients with low RFD almost reached significance for the LR group (P ¼ 0.103) and also for the HR group (P ¼ 0.09), which we interpret as lack of power in the subgroups.
The WBC count and MVD variable interacted significantly in the Cox analysis for the HR group. Indications of significant additive antagonistic interaction between MVD and RFD were also present. When constructing a combined variable based on these three variables the combination 'low WBC and low MVD and low RFD' identified a subset of patients with a pDFS of 100% (n ¼ 11). As a result of these facts and the low number of patients in the HR group (n ¼ 27), no multiple Cox analysis could be performed. Instead, we constructed a combination variable 'MVD/RFD', in order to study if combining the MVD and RFD variable could give further prognostic information. 9, 10 The statistical coding for the 'MVD/RFD' variable is illustrated in Figure 3 , where the survival curves are created for the LR and HR groups separately. When analyzing the whole set of patients the pDFS for the group of cases with low MVD and low RFD (8477%, n ¼ 40) was significantly higher compared to the rest of the patients -patients with high MVD, high RFD or both -(5778%, n ¼ 41, P ¼ 0.004). The same comparison was done separately for the LR and HR groups of patients in Figures 3b and c. In the LR group no significant difference in pDFS was found between the group of cases with low MVD and low RFD and the remaining group (P ¼ 0.222). However, when creating survival curves for the HR group of patients the difference in pDFS for the group of cases with low MVD in combination with low RFD (9277%, n ¼ 14) and the remaining group of patients with high MVD or high RFD (29713%, n ¼ 13) was distinct (P ¼ 0.002). No patient presented both high MVD and high RFD in the HR group.
In the present study, we found that evaluation of the BM stroma histology, which can be performed in core biopsies but not in aspirates, adds prognostic information.
MVD had prognostic impact for children treated for ALL with high-risk features and assessments of RFD for both high-and low-risk patients. We confirmed that measurements of MVD did not differ between the LR and the HR group and that MVD had no prognostic impact in the LR group. 2 Since our material was larger we could, however, analyze the HR group separately and a higher MVD was found in the relapsed than in the nonrelapsed HR-patients. Similarly higher RFD was found in the relapsed than in the nonrelapsed HR-patients. When combining the MVD and RFD variables in a survival curve for the HR group both a group with an extremely favorable outcome and a group with a significantly worse outcome were identified. These results suggest that the group of patients stratified to the HR group is very heterogeneous and that measuring MVD and RFD in the BM stroma might be a way to further subdivide this group into patients that do not benefit from additional intensification of treatment and those who do. However, as the patients in this study have been treated according to protocols with some differences, although with basically the same design, our results should be interpreted with some caution. To explore this further it is necessary to investigate a larger set of patients, where the outcome in each therapy stratification group can be analyzed separately in relation to vascular density and fibrosis. Vascular density measured in hot spots is a prognostic indicator in a wide variety of human cancers. 11 It is therefore not surprising that MVD was related to a poor outcome in childhood ALL HR patients in our study. Other methods for evaluation of vessel density have recently been described and it would be interesting to compare prognostic impact among different methods. 12 The observed correlation between the MVD and the WBC in the HR group has not been described before and needs to be confirmed. In this study, we also demonstrated that BM fibrosis was of prognostic significance in childhood ALL -as in adults with CML 4 -but the reason to this is unclear.
In conclusion, this study suggests that morphological estimation of vascular density and BM fibrosis by investigation of the BM stroma add prognostic information in childhood ALL and that further evaluation of correlations to other risk factors such as MRD and cytogenetics may contribute to the understanding of leukemia biology.
